Immunocompetent murine models for the study of glioblastoma immunotherapy

Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in clinical outcomes are modest, in no small part du...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Taemin, Fakurnejad, Shayan, Sayegh, Eli T, Clark, Aaron J, Ivan, Michael E, Sun, Matthew Z, Safaee, Michael, Bloch, Orin, James, Charles D, Parsa, Andrew T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012243/
https://www.ncbi.nlm.nih.gov/pubmed/24779345
http://dx.doi.org/10.1186/1479-5876-12-107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012243/
https://www.ncbi.nlm.nih.gov/pubmed/24779345
http://dx.doi.org/10.1186/1479-5876-12-107

Ejemplares similares